Management Team

Dror Ben-Asher , CEO

Dror Ben-Asher, Co-Founder of RedHill, was previously with ProSeed Capital, a European corporate finance boutique. Mr. Ben-Asher is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Mr. Ben-Asher was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror Ben-Asher received an LL.B. with distinction (First Class Honours) from the University of Leicester.

Reza Fathi PhD , Senior VP R&D

Prior to joining RedHill, Dr. Fathi served as Director of Research Operations at XTL Biopharmaceuticals. He was previously at VivoQuest, PharmaGenics, Metrigen, Enzo Biochem and the Harvard Institute of Chemistry and Cell Biology. Dr. Fathi graduated from Rutgers University (Ph.D. and Post-Doctoral Fellow) and Texas Tech University (BSc).

Gilead Raday , Chief Operating Officer

Gilead Raday previously served as interim CEO of Sepal Pharma, and as a director at TK Signal and Morria Biopharmaceuticals. He is a graduate of the University of Cambridge (M.Sc. in Bioscience Enterprise) and the Hebrew University of Jerusalem (M.Sc. Neurobiology, BSc Mathematics and Biology).

Adi Frish , Senior VP Business Development and Licensing

Adi Frish brings extensive business development and transactional experience to RedHill. Prior to joining RedHill, he served as VP Business Development at Medigus (TASE: MDGS). Mr. Frish was previously a partner at Y. Ben-Dror & Co. He is a graduate of Bar Ilan University (LL.M.) and Essex University (LL.B. with Honors).

Micha Ben Chorin , CFO

Mr. Ben Chorin has over 20 years of financial management experience with specific expertise in financing, M&A and international operations. He was a member of the team that built GVT (currently Telefonica Brazil). Most recently, Mr. Ben Chorin served as CFO of Pyramid Analytics and he previously served as CFO of Starhome B.V. Mr. Ben Chorin holds an M.A. and a B.A. from Tel-Aviv University and is a Certified Public Accountant. 

Guy Goldberg , Chief Business Officer

Prior to joining RedHill, Guy Goldberg served as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. Previously, Mr. Goldberg was a member of the investment team at ProQuest Investments, a healthcare focused venture capital firm. He previously served as a consultant at McKinsey & Company and holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.

Ira Kalfus MD , Medical Director

Prior to joining RedHill, Dr. Kalfus served as VP of Medical Affairs at Lev Pharmaceuticals. He was previously with Aetna/US Healthcare, Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed his residency in Internal Medicine at LIJ and is a graduate of the Albert Einstein College of Medicine (M.D.) and Columbia University (B.A. in Biology).

Terry F. Plasse MD , Medical Director

Dr. Plasse has extensive experience in drug development, primarily in oncology, having worked with several large as well as small pharmaceutical and biotech firms. He was previously Director for Oncology for North America at Rhone-Poulenc Rorer and served as a consultant to several major firms, including Chiron, Merck and Bristol-Myers Squibb. Dr. Plasse completed his fellowship in medical oncology at Mt Sinai Medical Center and his medical residency at Beth Israel Hospital, both in New York. He is a graduate of the Washington University School of Medicine, St. Louis, and received his BA from Brandeis University, in Waltham, MA.

Mark L. Levitt, MD, PhD, Medical Director, Oncology

Dr. Levitt is a Board Certified Medical Oncologist and Internist in the US and is Specialty Certified as an Oncologist (Medical and Radiation) and Internist in Israel. Prior to joining RedHill, Dr. Levitt served as Head of the Oncology Therapeutic Area, Global Business Development. Dr. Levitt also previously served as Head of the Lung Cancer Unit at Sheba Medical Center and held positions at Inotek Pharmaceuticals and in leading US universities. Dr. Levitt completed his internship and residency in Internal Medicine at Hahnemann University Hospital and his fellowship in Medical Oncology at the National Cancer Institute (NIH).

Craig Miller , VP US Business Operations, Market Access

Craig Miller has over 27 years of experience in the pharmaceutical industry, with extensive expertise in successfully designing and executing strategic commercialization plans and managing trade accounts. Prior to joining RedHill, Mr. Miller was with Salix Pharmaceuticals for 15 years, where he held positions of increasing responsibility and most recently served as Director of Trade Relation. Mr. Miller also previously served in commercial operations roles at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals

Shani Maurice , VP Business Development & Communications

Shani Maurice previously served as a Project Manager and as a Research Analyst at the Prime Minister’s Office, leading technological projects. She is a graduate of the Hebrew University of Jerusalem (B.Sc. in Biology and Business Administration).

Patricia Anderson , VP, Regulatory Affairs

Patricia Anderson has over 30 years of experience in regulatory affairs, developing numerous successful submissions to regulatory agencies across North America and Europe. Prior to joining RedHill, Ms. Anderson served as VP of Regulatory Services at MAPI SRS and as a member of the Executive Steering Committee for SRS, responsible for the business unit for regulatory consulting. She also served in various regulatory affairs positions at PharmApprove International Regulatory Consultants, Hyal Pharmaceutical Corporation and Bayer Canada. Ms. Anderson graduated with a B.Sc. in Biology from York University and a M.Sc. in Regulatory Affairs from University of Hertfordshire. Ms. Anderson received a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society and Ms. Anderson was also honored as a Fellow of the Regulatory Affairs Professional Society.

David Wasserman , VP Business Alliance and Compliance Officer

David Wasserman has over 33 years of experience in the pharmaceutical industry, with extensive expertise in domestic and global business Alliance Management, licensing and international distribution activities. Prior to joining RedHill, Mr. Wasserman served as Executive Director Global Business Alliance Management at Salix Pharmaceuticals, managing various areas of the Business Development Search and Evaluation Team. Mr. Wasserman has extensive experience in start-up and historically established companies and strong proficiencies in due diligence, business analytics, and product portfolio life cycle management. Prior to joining Salix, Mr. Wasserman was Director of Sales Training and Career Development at Watson Pharmaceuticals (now Actavis) and the Dermatology Division at Glaxo PLC. Mr. Wasserman has also help positions as a Regional Sales Manager at Astellas, PharmaDerm, and Oclassen Pharmaceuticals

Aida Bibliowicz , VP, Clinical Affairs Europe

Aida Bibliowicz has wide-ranging experience in drug development and clinical development international programs. Prior to joining RedHill Ms. Bibliowicz worked as Director, Project Management and Regulatory Affairs at Cato Research Israel, overseeing large multinational clinical studies in various indications. Ms. Bibliowicz holds a M.Sc. in Quality Assurance and Reliability from the Israel Institute of Technology, Technion, and an MBA from the Tel Aviv University.

Danielle Abramson , PhD, VP, Intellectual Property & Research

Danielle Abramson has extensive experience developing, analyzing, and managing intellectual property portfolios for Life Sciences and Medical Device companies. Ms. Abramson received her Bachelor of Science in Mechanical Engineering from Binghamton University and her Doctor of Philosophy in Medical Sciences from Brown University. Danielle Abramson is registered to practice as a patent agent before the U.S. Patent and Trademark Office. Prior to joining RedHill, Ms. Abramson practiced patent law at the international law firm of Greenberg Traurig.

Clara Fehrmann , Director of Clinical Operations

Clara Fehrmann has extensive R&D experience in the pharmaceutical industry acquired across large pharma, biotech as well as contract research companies. Prior to joining RedHill, she served as Clinical Project Manager at Merck Canada, Inc. and in various drug development positions at Santhera Pharmaceuticals. Ms. Fehrmann has also served as Clinical Research Associate at ICON Clinical Research (Canada), Inc. She graduated with a B.Sc. in Microbiology and Immunology from McGill University in Montreal and holds an M.Sc. degree in Pharmaceutical Sciences from the University of Montreal, Canada.

Valerie Graceffa , VP, US Sales and Marketing

Valerie Graceffa brings a wide-range of sales leadership expertise to RedHill Biopharma. Ms. Graceffa previously served as the Regional Sales Director for Aurora Diagnostics, as a Gastroenterology District Sales Manager for Warner Chilcott Pharmaceuticals and an Account Executive focusing on healthcare recruiting for the Trak Group, Management Recruiters International of Cincinnati. Graceffa is a graduate of Arizona State University.

Raymond M. Panas, PhD , Director of Medical Affairs

Raymond Panas has over 30 years of experience in clinical research and pharmaceutical development: beginning with laboratory research for HIV to the development of drug products for both US and European approvals to pharmacovigilance and most recently to medical affairs supporting medical education and investigator-initiated research. Dr. Panas was previously with TAP Pharmaceuticals, Sucampo Pharmaceuticals, Wellstat Therapeutics, and Entera Health. He has supported graduate students as adjunct faculty and dissertation advisor for The George Washington University, University of Liverpool and Walden University. Dr. Panas received his BS (Biology and Economics) and MPH (Community Health Services) from the University of Pittsburgh, and a PhD in Public Health (Health Education and Promotion) at Walden University. He is also certified as a Technologist in Immunology and a Certified Clinical Research Associate.

Patrick Mclean , Product Manager

Prior to joining RedHill, Patrick Mclean accumulated extensive experience in various senior executive positions in pharmaceutical companies including Giaconda Limited (CEO and Acting Chairman), Axcan Pharma (Senior VP European Commercial Operations, VP Sales & Marketing, Canada & US), Cossette Health Group (General Manager) and Allard Pharma Communications (President). Mr. Mclean graduated from the University of Minnesota (B.S. Chemistry).

Vered Katz Ben-Yair , Product Manager, Oncology

Prior to joining RedHill, Vered Katz Ben-Yair served as a Scientific Consultant in the international scientists team of Thomson Reuters. Ms. Katz Ben-Yair was previously with Selventa Inc, where she served in roles of increasing responsibility, most recently as a Scientist and Project Lead, leading collaborations with international pharmaceutical companies. Ms. Katz Ben-Yair studied towards a PhD in the Molecular Genetics Department at the Weizmann Institute in Rehovot and holds a M.Sc. and B.Sc. in Medical Sciences from the Hebrew University of Jerusalem.